| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | indacaterol/mometasone furoate (Atectura® Breezhaler®) |
| Formulation | 125/62.5, 125/127.5, 125/260 micrograms inhalation powder, hard capsules |
| Reference number | 4503 |
| Indication | As a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 21/05/2021 |